Company profile: Genome Diagnostics
1.1 - Company Overview
Company description
- Provider of in vitro diagnostic tests and services, molecular diagnostic kits, analysis software, and education for transplantation and companion diagnostics. Delivers sequencing-based, high-resolution HLA typing for Sanger and NGS, NGSgo workflows, Oxford Nanopore solutions (NGS-Pronto, NGS-Turbo), NGSengine-Turbo software, and chimerism monitoring assays and software (NGStrack, TRKengine).
Products and services
- NGSengine-Turbo: NGS-based HLA typing software developed for analyzing data from NGS-Turbo assays, featuring an intuitive interface and regular updates
- NGSgo Workflow: NGS-based comprehensive HLA typing workflow, visualized via instructional videos that outline standardized next-generation sequencing procedures
- NGS-Pronto: Oxford Nanopore–based complete sequencing system offering amplification and barcoded library preparation, delivering results in under 8 hours for up to 96 samples per run
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genome Diagnostics
YorkTest
HQ: United Kingdom
Website
- Description: Provider of food intolerance programs and diagnostic testing services, providing personalized information and support to help optimize health and wellbeing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full YorkTest company profile →
Lophius Biosciences
HQ: Germany
Website
- Description: Provider of innovative products for the diagnosis of acute infectious and autoimmune diseases, plus custom services in cell-based bioactivity and quality testing for pharmaceutical agents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lophius Biosciences company profile →
Escient Pharmaceuticals
HQ: United States
Website
- Description: Provider of bio-technical research and development services focused on advancing first-in-class G Protein-Coupled Receptor targeted drugs and therapies for neuro-immuno-inflammatory and autoreactive diseases. Pipeline includes EP262, an oral, once-daily small molecule MRGPRX2 antagonist for the potential treatment of mast cell-mediated diseases (including chronic urticarias and atopic dermatitis), and EP547, an oral, once-daily MRGPRX4 antagonist for cholestatic and uremic pruritus.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Escient Pharmaceuticals company profile →
Equillium
HQ: United States
Website
- Description: Provider of therapeutics for autoimmune and inflammatory disorders, including itolizumab, a clinical-stage monoclonal antibody targeting the CD6-ALCAM pathway; EQ101, a tri-specific cytokine inhibitor of IL-2/IL-9/IL-15 in Phase 2 for alopecia areata; EQ302, an oral bi-specific inhibitor of IL-15/IL-21 in pre-clinical; and a multi-cytokine platform generating composite peptides to selectively block key cytokines at shared receptors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Equillium company profile →
Graviton
HQ: United States
Website
- Description: Provider of clinical-stage biotech therapies, developing selective ROCK2 inhibitors for fibrotic, autoimmune and CNS diseases; a C6 monoclonal antibody for neurodegenerative diseases; and DYRK inhibitors for diabetes, neurological disorders and cancers. Conducts clinical trials and partners with Ovid Therapeutics and Sino Biopharmaceutical for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Graviton company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genome Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genome Diagnostics
2.2 - Growth funds investing in similar companies to Genome Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genome Diagnostics
4.2 - Public trading comparable groups for Genome Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →